Full Text View
Tabular View
No Study Results Posted
Related Studies
Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (DRIVE)
This study is ongoing, but not recruiting participants.
Study NCT00465894   Information provided by University of Alabama at Birmingham
First Received: April 23, 2007   Last Updated: September 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Overactive Bladder
Additional conditions recognized in this trial
Urinary Bladder, Overactive
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
tolterodine LA
Estrace Vaginal Cream
Additional drug interventions recognized in this trial
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate
Tolterodine
More general drug interventions related to this trial
Cholinergic Agents
Cholinergic Antagonists
Contraceptive Agents
Contraceptive Agents, Female
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
University of Alabama at Birmingham
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services